Brief: Vallon Pharmaceuticals Announces Topline Results Of Its Pivotal Seal Study For Lead Program, Adair, For The Treatment Of Adhd

GRI Bio

21/03/2022 11:41

March 21 (Reuters) - Vallon Pharmaceuticals Inc  VLON.O :
    * VALLON PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS OF ITS
PIVOTAL
SEAL STUDY FOR LEAD PROGRAM, ADAIR, FOR THE TREATMENT OF ADHD
    * VALLON PHARMACEUTICALS - STUDY DID NOT MEET PRIMARY
ENDPOINT
    * VALLON PHARMACEUTICALS INC - ALL PHARMACODYNAMIC SECONDARY
ENDPOINTS MET WITH STATISTICAL SIGNIFICANCE
    * VALLON PHARMACEUTICALS INC - ADAIR WAS GENERALLY WELL
TOLERATED
    * VALLON PHARMACEUTICALS - SAFETY PROFILE OF ALL ACTIVE
TREATMENT
ARMS CONSISTENT WITH KNOWN EFFECTS OF AMPHETAMINE, NO UNEXPECTED
ADVERSE EVENTS REPORTED
    * VALLON PHARMACEUTICALS INC - THERE WERE NO SERIOUS ADVERSE
EVENTS (SAES) REPORTED DURING STUDY IN ANY TREATMENT ARM
    * VALLON PHARMACEUTICALS INC - THERE WERE NO
DISCONTINUATIONS DUE
TO ADVERSE EVENTS

Source text for Eikon:  ID:nGNXbnfzKw 
Further company coverage:  VLON.O 

 ((Reuters.Briefs@thomsonreuters.com;))